Skip to main content

Table 1 Patient and tumor characteristics in the evaluated cohort and in subgroups according to gender

From: Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study

  All, n = 527 Female, n = 276 (52.4%) Male, n = 251 (47.6%) P valuea
Age     
   Mean 70.5 70.6 70.4 0.399
   Median 71.4 72 70.9  
   Range 49.8 to 85.6 49.8 to 85.2 51.8 to 85.6  
Location     
   Colon 323 (61.3) 176 (63.8) 147 (58.6) 0.256
   Rectum 190 (36.1) 92 (33.3) 98 (39.0)  
   Multiple 12 (2.3) 7 (2.5) 5 (2.0)  
   Unknown 2 (0.4) 1 (0.4) 1 (0.4)  
T Stage     
   1 46 (8.7) 31 (11.2) 15 (6.0) 0.506
   2 63 (12.0) 30 (10.9) 33 (13.1)  
   3 319 (60.5) 159 (57.6) 160 (63.7)  
   4 78 (14.8) 42 (15.2) 36 (14.3)  
Unknown 21 (4.0) 39 (12.0) 38 (12.7)  
N stage     
   0 278 (52.8) 144 (52.2) 134 (53.4) 0.494
   1 118 (22.4) 68 (24.6) 50 (19.9)  
   2 85 (16.1) 36 (13.0) 49 (19.5)  
   Unknown 46 (8.7) 28 (10.1) 18 (7.2)  
M Stage     
   0 429 (81.4) 226 (81.9) 203 (80.9) 0.513
   1 90 (17.1) 44 (15.9) 46 (18.3)  
   Unknown 8 (1.5) 6 (2.2) 2 (0.8)  
Differentiation grade     
   High 34 (6.5) 19 (6.9) 15 (6.0) 0.438
   Intermediate 367 (69.6) 185 (67.0) 182 (72.5)  
   Low 118 (22.4) 67 (24.3) 51 (20.3)  
   Unknown 8 (1.5) 5 (1.8) 3 (1.2)  
Vascular invasion     
   No 150 (28.5) 81 (29.3) 69 (27.5) 0.635
   Yes 156 (29.6) 80 (29.0) 76 (30.3)  
   Unknown 222 (41.9) 115 (41.7) 106 (42.2)  
Surgery     
   Acute 46 (8.7) 26 (9.4) 20 (8.0) 0.502
   Elective 454 (86.1) 233 (84.4) 221 (88.0)  
   Unknown 27 (5.1) 17 (6.2) 10 (4.0)  
Neodjuvant treatment     
   None 414 (78.6) 216 (83.4) 198 (82.2) 0.291
   Short RT 25 (4.7) 10 (3.9) 15 (6.2)  
   Long RT 19 (3.6) 8 (3.1) 11 (4.6)  
   Chemotherapy + RT 2 (0.4) 2 (0.8) 0 (0.0)  
   Chemotherapy 2 (0.4) 1 (0.4) 1 (0.4)  
   Unknown 65 (12.3) 39 (14.1) 16 (10.4)  
Adjuvant treatment     
   No 294 (55.8) 149 (54.0.8) 145 (57.8) 0.584
   FLV/Xeloda 51 (9.7) 25 (9.1) 26 (10.4)  
   FLOX/XELOX 19 (3.6) 11 (4.0) 8 (3.2)  
   Other 5 (0.9) 4 (1.4) 1 (0.4)  
   Curative; M1* 14 (2.7) 6 (2.2) 8 (3.2)  
   Palliative 80 (15.2) 39 (14.1) 41 (16.3)  
   Unknown 64 (12.1) 42 (15.2) 22 (8.8)  
Follow-up (years)     
   Mean 4.7 4,9 4.5 0.399
   Median 3.5 3.4 3.4  
   Range 0.0 to 17.7 0.0 to 17.7 0.0 to 16.6  
Vital status     
   Alive 306 (58.1) 169 (61.2) 137 (54.6) 0.113
   Dead 221 (41.9) 107 (38.8) 114 (45.4)  
   Dead from CRC 182 (34.5) 90 (32.6) 92 (36.7) 0.313
Follow-up (years); M1 patients     
   Mean 1.5 1.3 1.6 0.129
   Median 1.1 0.8 1.2  
   Range 0.0 to 6.1 0.0 to 5.5 0.0 to 6.1  
Vital status; M1 patients     
   Alive 12 (13.3) 7 (15.9) 5 (10.9) 0.484
   Dead 78 (86.7) 37 (84.1) 41 (89.1)  
   Dead from CRC 78 (86.7) 37 (84.1) 41 (89.1) 0.484
Cyclin D1 fraction     
   0 to 1 105 (19.9) 50 (18.1) 55 (21.9) 0.217
   02 to 25 195 (37.0) 100 (36.2) 95 (37.8)  
   26 to 50 86 (16.3) 48 (17.4) 38 (15.1)  
   51 to 75 112 (21.3) 64 (23.2) 48 (19.1)  
   > 75 29 (5.5) 14 (5.1) 15 (6.0)  
Cyclin D1 intensity     
   Negative 105 (19.9) 50 (18.1) 55 (21.9) 0.018
   Weak 181 (34.3) 85 (30.8) 96 (38.2)  
   Moderate 176 (33.4) 102 (37.0) 74 (29.5)  
   Strong 65 (12.3) 39 (14.1) 26 (10.4)  
  1. aThe P values refer to comparisons of male and female tumors, using the Mann-WhitneyU-test for comparison of medians and the χ2 test for X × 2 tables. P-values for vital status refer to overall and cause-specific death, respectively. The categories marked as 'not done' and 'unknown' were not included in the statistical analysis.
  2. Abbreviations: FLOX = 5-fluorouracil, leucovorin and oxaliplatin, FLV = 5-fluorouracil and leucovorin, RT = radiotherapy, XELOX = Xeloda (capecitabine) and oxaliplatin.